London (UK) June 25th , 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), clinical-stage biopharmaceutical company pioneering novel anti-cancer therapies targeting the tumor microenvironment, announced today that it has received an updated equity research report from Sphene Capital, a prestigious German equity research firm, assigning the company a “Buy” rating and a significantly increased valuation..
Vidac Pharma announced today that it has received an updated equity research report from Sphene Capital, a respected German investment firm, assigning the company a “Buy” rating and a significantly increased valuation.
The independent analyst report highlights Vidac’s differentiated therapeutic platform, ongoing clinical advancements, and strong long-term potential in the oncology space.
Sphene Capital emphasized Vidac’s proprietary metabolic disruption strategy, which focuses on reversing the Warburg effect—a hallmark of cancer cell metabolism. The firm’s lead candidate, VDA-1102, is currently in Phase II clinical trials for cutaneous T-cell lymphoma (CTCL) and has demonstrated encouraging efficacy and safety results.
“We are pleased to see growing recognition from the investment community of Vidac Pharma’s scientific leadership and clinical momentum,” said Dr. Max Herzberg, Founder and Executive Chairman of Vidac Pharma. “This independent 'Buy' rating reflects the strength of our pipeline and the value creation potential we offer as we progress toward registration.”
The report also noted Vidac’s experienced leadership, robust intellectual property portfolio, and strategic positioning in addressing unmet medical needs in oncology—key factors underpinning the company’s investment appeal.
Full report available at https://vidacpharma.com/en/investor-relations
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.